# A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

Source: https://onco.cc/trials/nct06864169/  
OnCo record `nct06864169` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Raludotatug deruxtecan in advanced solid tumours, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) is a phase 2 interventional study registered as NCT06864169 by Merck Sharp & Dohme LLC, with 160 participants enrolled, started 2025-04-01 and due to reach its primary completion in 2026-08-18. Interventions recorded: Raludotatug Deruxtecan (R-DXd).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06864169
- Phase: 2
- Setting: A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT06864169: https://clinicaltrials.gov/study/NCT06864169

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Raludotatug deruxtecan](https://onco.cc/drugs/raludotatug-deruxtecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06864169.json